Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease

Marie E. Edwards, Fouad Chebib, Maria Irazabal Mira, Troy G. Ofstie, Lisa A. Bungum, Andrew J. Metzger, Sarah R. Senum, Marie C Hogan, Ziad M El-Zoghby, Timothy Kline, Peter C Harris, Frank S. Czerwiec, Vicente Torres

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background and objectives In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy. Design, setting, participants, & measurements One hundred and twenty-eight patients with autosomal dominant polycystic kidney disease participated in clinical trials of tolvaptan at the Mayo Clinic. All had the opportunity to enroll into open-label extension studies. Twenty participated in short-term studies or received placebo only. The remaining 108 were analyzed for safety. Ninety seven patients treated with tolvaptan for ≥1 year (mean±SD, 4.662.8; range, 1.1–11.2) were analyzed for efficacy using three approaches: (1) comparison of eGFR slopes and outcome (33% reduction from baseline eGFR) to controls matched by sex, age, and baseline eGFR; (2) Stability of eGFR slopes with duration of follow-up; and (3) comparison of observed and predicted eGFRs at last follow-up. Results Patients treated with tolvaptan had lower eGFR slopes from baseline (mean±SD,–2.20±2.18ml/min per 1.73m2 per year) and from month 1 (mean±SD,–1.97±2.44 ml/min per 1.73m2 per year) compared with controls (mean±SD, 23.50±2.09 ml/min per 1.73 m2 per year; P<0.001), and lower risk of a 33% reduction in eGFR (risk ratio, 0.63; 95%confidence interval, 0.38 to 0.98 from baseline; risk ratio, 0.53; 95%confidence interval, 0.31 to 0.85 from month 1). Annualized eGFR slopes of patients treated with tolvaptan did not change during follow-up and differences between observed and predicted eGFRs at last follow-up increased with duration of treatment. Conclusions Follow-up for up to 11.2 years (average 4.6 years) showed a sustained reduction in the annual rate of eGFR decline in patients treated with tolvaptan compared with controls and an increasing separation of eGFR values over time between the two groups.

Original languageEnglish (US)
Pages (from-to)1153-1161
Number of pages9
JournalClinical Journal of the American Society of Nephrology
Volume13
Issue number8
DOIs
StatePublished - Aug 7 2018

Fingerprint

Autosomal Dominant Polycystic Kidney
Odds Ratio
Confidence Intervals
Safety
Safety Management
tolvaptan
Renal Replacement Therapy
Placebos
Clinical Trials
Kidney

Keywords

  • ADPKD
  • Benzazepines
  • Chronic kidney disease
  • EGFR protein, human
  • Follow-Up Studies
  • Glomerular filtration rate
  • Humans
  • Polycystic kidney disease
  • Polycystic Kidney, Autosomal Dominant
  • Receptor, Epidermal Growth Factor
  • Renal Insufficiency, Chronic
  • Renal Replacement Therapy
  • TEMPO
  • Tolvaptan
  • Vasopressin
  • Vasopressin Receptor Antagonist

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. / Edwards, Marie E.; Chebib, Fouad; Irazabal Mira, Maria; Ofstie, Troy G.; Bungum, Lisa A.; Metzger, Andrew J.; Senum, Sarah R.; Hogan, Marie C; El-Zoghby, Ziad M; Kline, Timothy; Harris, Peter C; Czerwiec, Frank S.; Torres, Vicente.

In: Clinical Journal of the American Society of Nephrology, Vol. 13, No. 8, 07.08.2018, p. 1153-1161.

Research output: Contribution to journalArticle

@article{ac59a61bb1d74784b339e915aabdf58e,
title = "Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease",
abstract = "Background and objectives In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy. Design, setting, participants, & measurements One hundred and twenty-eight patients with autosomal dominant polycystic kidney disease participated in clinical trials of tolvaptan at the Mayo Clinic. All had the opportunity to enroll into open-label extension studies. Twenty participated in short-term studies or received placebo only. The remaining 108 were analyzed for safety. Ninety seven patients treated with tolvaptan for ≥1 year (mean±SD, 4.662.8; range, 1.1–11.2) were analyzed for efficacy using three approaches: (1) comparison of eGFR slopes and outcome (33{\%} reduction from baseline eGFR) to controls matched by sex, age, and baseline eGFR; (2) Stability of eGFR slopes with duration of follow-up; and (3) comparison of observed and predicted eGFRs at last follow-up. Results Patients treated with tolvaptan had lower eGFR slopes from baseline (mean±SD,–2.20±2.18ml/min per 1.73m2 per year) and from month 1 (mean±SD,–1.97±2.44 ml/min per 1.73m2 per year) compared with controls (mean±SD, 23.50±2.09 ml/min per 1.73 m2 per year; P<0.001), and lower risk of a 33{\%} reduction in eGFR (risk ratio, 0.63; 95{\%}confidence interval, 0.38 to 0.98 from baseline; risk ratio, 0.53; 95{\%}confidence interval, 0.31 to 0.85 from month 1). Annualized eGFR slopes of patients treated with tolvaptan did not change during follow-up and differences between observed and predicted eGFRs at last follow-up increased with duration of treatment. Conclusions Follow-up for up to 11.2 years (average 4.6 years) showed a sustained reduction in the annual rate of eGFR decline in patients treated with tolvaptan compared with controls and an increasing separation of eGFR values over time between the two groups.",
keywords = "ADPKD, Benzazepines, Chronic kidney disease, EGFR protein, human, Follow-Up Studies, Glomerular filtration rate, Humans, Polycystic kidney disease, Polycystic Kidney, Autosomal Dominant, Receptor, Epidermal Growth Factor, Renal Insufficiency, Chronic, Renal Replacement Therapy, TEMPO, Tolvaptan, Vasopressin, Vasopressin Receptor Antagonist",
author = "Edwards, {Marie E.} and Fouad Chebib and {Irazabal Mira}, Maria and Ofstie, {Troy G.} and Bungum, {Lisa A.} and Metzger, {Andrew J.} and Senum, {Sarah R.} and Hogan, {Marie C} and El-Zoghby, {Ziad M} and Timothy Kline and Harris, {Peter C} and Czerwiec, {Frank S.} and Vicente Torres",
year = "2018",
month = "8",
day = "7",
doi = "10.2215/CJN.01520218",
language = "English (US)",
volume = "13",
pages = "1153--1161",
journal = "Clinical Journal of the American Society of Nephrology",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "8",

}

TY - JOUR

T1 - Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease

AU - Edwards, Marie E.

AU - Chebib, Fouad

AU - Irazabal Mira, Maria

AU - Ofstie, Troy G.

AU - Bungum, Lisa A.

AU - Metzger, Andrew J.

AU - Senum, Sarah R.

AU - Hogan, Marie C

AU - El-Zoghby, Ziad M

AU - Kline, Timothy

AU - Harris, Peter C

AU - Czerwiec, Frank S.

AU - Torres, Vicente

PY - 2018/8/7

Y1 - 2018/8/7

N2 - Background and objectives In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy. Design, setting, participants, & measurements One hundred and twenty-eight patients with autosomal dominant polycystic kidney disease participated in clinical trials of tolvaptan at the Mayo Clinic. All had the opportunity to enroll into open-label extension studies. Twenty participated in short-term studies or received placebo only. The remaining 108 were analyzed for safety. Ninety seven patients treated with tolvaptan for ≥1 year (mean±SD, 4.662.8; range, 1.1–11.2) were analyzed for efficacy using three approaches: (1) comparison of eGFR slopes and outcome (33% reduction from baseline eGFR) to controls matched by sex, age, and baseline eGFR; (2) Stability of eGFR slopes with duration of follow-up; and (3) comparison of observed and predicted eGFRs at last follow-up. Results Patients treated with tolvaptan had lower eGFR slopes from baseline (mean±SD,–2.20±2.18ml/min per 1.73m2 per year) and from month 1 (mean±SD,–1.97±2.44 ml/min per 1.73m2 per year) compared with controls (mean±SD, 23.50±2.09 ml/min per 1.73 m2 per year; P<0.001), and lower risk of a 33% reduction in eGFR (risk ratio, 0.63; 95%confidence interval, 0.38 to 0.98 from baseline; risk ratio, 0.53; 95%confidence interval, 0.31 to 0.85 from month 1). Annualized eGFR slopes of patients treated with tolvaptan did not change during follow-up and differences between observed and predicted eGFRs at last follow-up increased with duration of treatment. Conclusions Follow-up for up to 11.2 years (average 4.6 years) showed a sustained reduction in the annual rate of eGFR decline in patients treated with tolvaptan compared with controls and an increasing separation of eGFR values over time between the two groups.

AB - Background and objectives In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy. Design, setting, participants, & measurements One hundred and twenty-eight patients with autosomal dominant polycystic kidney disease participated in clinical trials of tolvaptan at the Mayo Clinic. All had the opportunity to enroll into open-label extension studies. Twenty participated in short-term studies or received placebo only. The remaining 108 were analyzed for safety. Ninety seven patients treated with tolvaptan for ≥1 year (mean±SD, 4.662.8; range, 1.1–11.2) were analyzed for efficacy using three approaches: (1) comparison of eGFR slopes and outcome (33% reduction from baseline eGFR) to controls matched by sex, age, and baseline eGFR; (2) Stability of eGFR slopes with duration of follow-up; and (3) comparison of observed and predicted eGFRs at last follow-up. Results Patients treated with tolvaptan had lower eGFR slopes from baseline (mean±SD,–2.20±2.18ml/min per 1.73m2 per year) and from month 1 (mean±SD,–1.97±2.44 ml/min per 1.73m2 per year) compared with controls (mean±SD, 23.50±2.09 ml/min per 1.73 m2 per year; P<0.001), and lower risk of a 33% reduction in eGFR (risk ratio, 0.63; 95%confidence interval, 0.38 to 0.98 from baseline; risk ratio, 0.53; 95%confidence interval, 0.31 to 0.85 from month 1). Annualized eGFR slopes of patients treated with tolvaptan did not change during follow-up and differences between observed and predicted eGFRs at last follow-up increased with duration of treatment. Conclusions Follow-up for up to 11.2 years (average 4.6 years) showed a sustained reduction in the annual rate of eGFR decline in patients treated with tolvaptan compared with controls and an increasing separation of eGFR values over time between the two groups.

KW - ADPKD

KW - Benzazepines

KW - Chronic kidney disease

KW - EGFR protein, human

KW - Follow-Up Studies

KW - Glomerular filtration rate

KW - Humans

KW - Polycystic kidney disease

KW - Polycystic Kidney, Autosomal Dominant

KW - Receptor, Epidermal Growth Factor

KW - Renal Insufficiency, Chronic

KW - Renal Replacement Therapy

KW - TEMPO

KW - Tolvaptan

KW - Vasopressin

KW - Vasopressin Receptor Antagonist

UR - http://www.scopus.com/inward/record.url?scp=85051417285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051417285&partnerID=8YFLogxK

U2 - 10.2215/CJN.01520218

DO - 10.2215/CJN.01520218

M3 - Article

C2 - 30026287

AN - SCOPUS:85051417285

VL - 13

SP - 1153

EP - 1161

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

SN - 1555-9041

IS - 8

ER -